Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Phase 2b Dose-Response Study  Christopher R. Chapple, Jerzy Lorenz, Raymond Mortensen, Harald Pauthner, Mario O. Reis, Claude C. Schulman, Ingrid van der Putten-Slob  European Urology Supplements  Volume 4, Issue 2, Pages 25-32 (February 2005) DOI: 10.1016/j.eursup.2004.10.009 Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 1 Flow diagram of the number of patients enrolled, randomised and completing the study per treatment group. European Urology Supplements 2005 4, 25-32DOI: (10.1016/j.eursup.2004.10.009) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 2 Mean change in total I-PSS from baseline to endpoint (ITT). p-value for mean difference between tamsulosin OCAS and placebo. European Urology Supplements 2005 4, 25-32DOI: (10.1016/j.eursup.2004.10.009) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 3 Effect of treatment on mean total I-PSS over time (ITT). European Urology Supplements 2005 4, 25-32DOI: (10.1016/j.eursup.2004.10.009) Copyright © 2004 Elsevier B.V. Terms and Conditions